Logo

Voyager Therapeutics Provides Update on NBIB-1817 (VY-AADC) Program to Treat Parkinson Disease

Share this
Voyager Therapeutics Provides Update on NBIB-1817 (VY-AADC) Program to Treat Parkinson Disease

Voyager Therapeutics Provides Update on NBIB-1817 (VY-AADC) Program to Treat Parkinson Disease

Shots:

  • The P-ll RESTORE-1 study involves assessing NBIb-1817(VY-AADC) for the treatment of Parkinson's disease. Neurocrine & Voyager will closely work with FDA & DCMB to determine the next clinical trial for RESTORE-1
  • DSMB request a clinical hold- follows the IND Safety Report submit by Neurocrine Biosciences related to the observation of MRI abnormalities in some RESTORE-1 study participants and requested additional patient-level data from the trial and plans to review data in early 2021
  • NBIb-1817 is an investigational recombinant AAV serotype 2 vectors encoding the gene for human AADC help to produce AADC enzyme in brain cells & convert levodopa to dopamine

 ­ Ref: GlobeNewswire  | Image: PR Newswire

Click here to­ read the full press release 

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions